SYNLAB Pharma
SYNLAB Pharma is a segment of the Business Unit SYNLAB Analytics & Services
Germany GmbH of the SYNLAB Group and offers a very broad range of laboratory
services to the biotechnology, pharmaceutical and cosmetic industries as well as
to manufacturers of medical devices and novel foods. Our clients take advantage
of our large spectrum of analytical methods for drug development and production
control; always working in accordance with the highest standards such as DIN/EN,
ISO/IEC, 17025/15189, GMP, GLP, GCLP or GCP.
Our portfolio at SYNLAB Pharma includes global clinical trial services,
bioanalytical services, advanced biomarker testing, personalized medicine
concepts, sample logistics, long-term sample storage services, production
monitoring incl. extractables & leachables, product release and stability
studies.
SYNLAB Pharma supports the complete drug development cycle from preclinical
toxicology and PK projects through all clinical phases and beyond by offering
lab services for companion diagnostics and personalised medicine. Our
portfolio ranges from the measurement of single assays to the execution of
complex and demanding projects required for developing your medical product.
Headquartered in Munich, Germany, SYNLAB is Europe´s number one medical
diagnostics service provider, offering the full range of medical laboratory
services for patients, physicians, hospitals and the pharmaceutical industry.
SYNLAB combines the benefits of an European wide network of medical expertise
with the advantages of a local diagnostic services provider.
SYNLAB at a glance:
– Present in more than 35 countries on 4 continents
– More than 300 laboratories
– Approx. 500 million tests per annum
– More than 1.000 medical experts throughout the SYNLAB group
Choose us as your ONE-STOP-SHOP supporting the development of your medical
product incl. routine as well as specialized lab testing and take advantage
of our extensive experience gained from conducting successfully more than
3,500 preclinical and clinical trials and projects in more than 25 years.
